{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:31:20Z","timestamp":1790134280108,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11897-025-00734-9","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:37:19Z","timestamp":1764401839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current Achievements in Gene Therapy Strategies and Delivery Systems in Preclinical and Clinical Models of Heart Failure"],"prefix":"10.1007","volume":"22","author":[{"given":"Sarah","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Wittlieb-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Rossano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"issue":"8","key":"734_CR1","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke Statistics-2022 update: a report from the American heart association. Circulation. 2022;145(8):e153-639.","journal-title":"Circulation"},{"issue":"3","key":"734_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cardfail.2021.12.017","volume":"28","author":"PaulA Heidenreich","year":"2022","unstructured":"Heidenreich Paul A, et al. Economic issues in heart failure in the United States. J Card Fail. 2022;28(3):453\u201366. https:\/\/doi.org\/10.1016\/j.cardfail.2021.12.017.","journal-title":"J Card Fail"},{"issue":"4","key":"734_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.hoc.2022.05.001","volume":"36","author":"HL Malech","year":"2022","unstructured":"Malech HL, Garabedian EK, Hsieh MM. Evolution of gene therapy, historical perspective. Hematol Oncol Clin North Am. 2022;36(4):627\u201345. https:\/\/doi.org\/10.1016\/j.hoc.2022.05.001.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"734_CR4","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1038\/s41467-022-31686-6","volume":"13","author":"L Gerasimavicius","year":"2022","unstructured":"Gerasimavicius L, Livesey BJ, Marsh JA. Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure. Nat Commun. 2022;13(1):3895. https:\/\/doi.org\/10.1038\/s41467-022-31686-6. PMID: 35794153; PMCID: PMC9259657.","journal-title":"Nat Commun"},{"issue":"3","key":"734_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.04.096","volume":"19","author":"Jasmine Chebli","year":"2025","unstructured":"Chebli Jasmine, et al. Long-term monitoring of LPL gene replacement therapy: a lexicon of lessons for gene editing or oligonucleotide-based lipid lowering treatment. J Clin Lipidol. 2025;19(3):e69.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"734_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/blood.2022016196","volume":"140","author":"GDE Cuvelier","year":"2022","unstructured":"Cuvelier GDE, Logan BR, Prockop SE, Buckley RH, Kuo CY, Griffith LM, Liu X, Yip A, Hershfield MS, Ayoub PG, Moore TB, Dorsey MJ, O\u2019Reilly RJ, Kapoor N, Pai SY, Kapadia M, Ebens CL, Forbes Satter LR, Burroughs LM, Petrovic A, Chellapandian D, Heimall J, Shyr DC, Rayes A, Bednarski JJ, Chandra S, Chandrakasan S, Gillio AP, Madden L, Quigg TC, Caywood EH, D\u00e1vila Salda\u00f1a BJ, DeSantes K, Eissa H, Goldman FD, Rozmus J, Shah AJ, Vander Lugt MT, Thakar MS, Parrott RE, Martinez C, Leiding JW, Torgerson TR, Pulsipher MA, Notarangelo LD, Cowan MJ, Dvorak CC, Haddad E, Puck JM, Kohn DB. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. Blood. 2022;140(7):685\u2013705. https:\/\/doi.org\/10.1182\/blood.2022016196. PMID: 35671392; PMCID: PMC9389638.","journal-title":"Blood"},{"issue":"1","key":"734_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1161\/01.res.61.1.70","volume":"61","author":"JK Gwathmey","year":"1987","unstructured":"Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987;61(1):70\u20136. https:\/\/doi.org\/10.1161\/01.res.61.1.70.","journal-title":"Circ Res"},{"issue":"11","key":"734_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jacc.2007.12.014","volume":"51","author":"Y Kawase","year":"2008","unstructured":"Kawase Y, Ly HQ, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51(11):1112\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2007.12.014.","journal-title":"J Am Coll Cardiol"},{"issue":"10024","key":"734_CR9","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","volume":"387","author":"B Greenberg","year":"2016","unstructured":"Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387(10024):1178\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(16)00082-9.","journal-title":"Lancet"},{"issue":"12","key":"734_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","volume":"27","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Babalis D, Morley-Smith AC, et al. Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD trial. Gene Ther. 2020;27(12):579\u201390. https:\/\/doi.org\/10.1038\/s41434-020-0171-7.","journal-title":"Gene Ther"},{"issue":"3","key":"734_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0167-4889(96)00097-3","volume":"1313","author":"A Remppis","year":"1996","unstructured":"Remppis A, Greten T, Sch\u00e4fer BW, et al. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta. 1996;1313(3):253\u20137. https:\/\/doi.org\/10.1016\/0167-4889(96)00097-3.","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"734_CR12","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1161\/CIRCULATIONAHA.106.622415","volume":"114","author":"P Most","year":"2006","unstructured":"Most P, Seifert H, Gao E, et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation. 2006;114(12):1258\u201368. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.622415.","journal-title":"Circulation"},{"issue":"6","key":"734_CR13","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.ymthe.2005.08.002","volume":"12","author":"ST Pleger","year":"2005","unstructured":"Pleger ST, Remppis A, Heidt B, et al. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther. 2005;12(6):1120\u20139. https:\/\/doi.org\/10.1016\/j.ymthe.2005.08.002.","journal-title":"Mol Ther"},{"issue":"36","key":"734_CR14","doi-asserted-by":"publisher","first-page":"33809","DOI":"10.1074\/jbc.M301788200","volume":"278","author":"P Most","year":"2003","unstructured":"Most P, Remppis A, Pleger ST, et al. Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem. 2003;278(36):33809\u201317. https:\/\/doi.org\/10.1074\/jbc.M301788200.","journal-title":"J Biol Chem"},{"issue":"9","key":"734_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.jacc.2011.03.054","volume":"58","author":"Henriette Brinks","year":"2011","unstructured":"Brinks Henriette, et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol. 2011;58(9):966\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2011.03.054.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"734_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJM198207223070401","volume":"307","author":"MR Bristow","year":"1982","unstructured":"Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307(4):205\u201311. https:\/\/doi.org\/10.1056\/NEJM198207223070401.","journal-title":"N Engl J Med"},{"issue":"5","key":"734_CR17","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1172\/JCI117219","volume":"93","author":"Y Ishikawa","year":"1994","unstructured":"Ishikawa Y, Sorota S, Kiuchi K, et al. Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J Clin Invest. 1994;93(5):2224\u20139. https:\/\/doi.org\/10.1172\/JCI117219.","journal-title":"J Clin Invest"},{"issue":"2","key":"734_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","volume":"1","author":"HK Hammond","year":"2016","unstructured":"Hammond HK, Penny WF, Traverse JH, et al. Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol. 2016;1(2):163\u201371. https:\/\/doi.org\/10.1001\/jamacardio.2016.0008.","journal-title":"JAMA Cardiol"},{"key":"734_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.952755","volume":"9","author":"Huili Zhang","year":"2022","unstructured":"Zhang Huili, et al. AAV-mediated gene therapy: advancing cardiovascular disease treatment. Front Cardiovasc Med. 2022;9:952755. https:\/\/doi.org\/10.3389\/fcvm.2022.952755.","journal-title":"Front Cardiovasc Med"},{"issue":"2\u20133","key":"734_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0167-5273(02)00554-5","volume":"90","author":"G Vassalli","year":"2003","unstructured":"Vassalli G, B\u00fceler H, Dudler J, von Segesser LK, Kappenberger L. Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J Cardiol. 2003;90(2\u20133):229\u201338. https:\/\/doi.org\/10.1016\/s0167-5273(02)00554-5.","journal-title":"Int J Cardiol"},{"issue":"11","key":"734_CR21","first-page":"1612","volume":"164","author":"B Sibbald","year":"2001","unstructured":"Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ Can Med Assoc J. 2001;164(11):1612.","journal-title":"CMAJ Can Med Assoc J"},{"issue":"11","key":"734_CR22","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"1","author":"D Duan","year":"2023","unstructured":"Duan D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;1(11):3123\u20136. https:\/\/doi.org\/10.1016\/j.ymthe.2023.10.015.","journal-title":"Mol Ther"},{"issue":"Pt 11","key":"734_CR23","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1099\/vir.0.19497-0","volume":"84","author":"AJ Davison","year":"2003","unstructured":"Davison AJ, Benk\u0151 M, Harrach B. Genetic content and evolution of adenoviruses. J Gen Virol. 2003;84(Pt 11):2895\u2013908. https:\/\/doi.org\/10.1099\/vir.0.19497-0.","journal-title":"J Gen Virol"},{"issue":"2","key":"734_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","volume":"29","author":"D Reichart","year":"2023","unstructured":"Reichart D, Newby GA, Wakimoto H, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023;29(2):412\u201321. https:\/\/doi.org\/10.1038\/s41591-022-02190-7.","journal-title":"Nat Med"},{"key":"734_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103553","volume":"74","author":"Barnabas Wilson","year":"2022","unstructured":"Wilson Barnabas, Geetha Kannoth Mukundan. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J Drug Deliv Sci Technol. 2022;74:103553. https:\/\/doi.org\/10.1016\/j.jddst.2022.103553.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5","key":"734_CR26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.yjmcc.2010.09.003","volume":"50","author":"MichaelG Katz","year":"2011","unstructured":"Katz Michael G, et al. Current strategies for myocardial gene delivery. J Mol Cell Cardiol. 2011;50(5):766\u201376. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.09.003.","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"734_CR27","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/01.res.73.6.1202","volume":"73","author":"RJ Guzman","year":"1993","unstructured":"Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res. 1993;73(6):1202\u20137. https:\/\/doi.org\/10.1161\/01.res.73.6.1202.","journal-title":"Circ Res"},{"issue":"4","key":"734_CR28","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1006\/jmcc.1998.0905","volume":"31","author":"JC Zhang","year":"1999","unstructured":"Zhang JC, Woo YJ, Chen JA, Swain JL, Sweeney HL. Efficient transmural cardiac gene transfer by intrapericardial injection in neonatal mice. J Mol Cell Cardiol. 1999;31(4):721\u201332. https:\/\/doi.org\/10.1006\/jmcc.1998.0905.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"734_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","volume":"114","author":"K Zsebo","year":"2014","unstructured":"Zsebo K, Yaroshinsky A, Rudy JJ, et al. Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014;114(1):101\u20138. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.302421.","journal-title":"Circ Res"},{"issue":"6","key":"734_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/hum.2014.157","volume":"26","author":"NC Lai","year":"2015","unstructured":"Lai NC, Gao MH, Giamouridis D, Suarez J, Miyanohara A, Parikh J, et al. Intravenous AAV8 encoding urocortin-2 increases function of the failing heart in mice. Hum Gene Ther. 2015;26(6):347\u201356. https:\/\/doi.org\/10.1089\/hum.2014.157.","journal-title":"Hum Gene Ther"},{"key":"734_CR31","unstructured":"Taylor MRG, Adler ED. Danon disease. In: Adam MP, Feldman J, Mirzaa GM,Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. Seattle(WA): University of Washington, Seattle; 2020;5. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554742\/."},{"issue":"6","key":"734_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.120.003117","volume":"13","author":"D Lotan","year":"2020","unstructured":"Lotan D, Salazar-Mendiguch\u00eda J, Mogensen J, et al. Clinical profile of cardiac involvement in Danon disease: a multicenter European registry. Circ Genom Precis Med. 2020;13(6):e003117. https:\/\/doi.org\/10.1161\/CIRCGEN.120.003117.","journal-title":"Circ Genom Precis Med"},{"issue":"7","key":"734_CR33","doi-asserted-by":"publisher","first-page":"e038394","DOI":"10.1161\/JAHA.124.038394","volume":"14","author":"KN Hong","year":"2025","unstructured":"Hong KN, Eshraghian E, Khedro T, et al. An international longitudinal natural history study of patients with Danon disease: unique cardiac trajectories identified based on sex and heart failure outcomes. J Am Heart Assoc. 2025;14(7):e038394. https:\/\/doi.org\/10.1161\/JAHA.124.038394.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"734_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","volume":"7","author":"RS D\u2019souza","year":"2014","unstructured":"D\u2019souza RS, et al. Danon disease: clinical features, evaluation, and management. Circ Heart Fail. 2014;7(5):843\u20139. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001105.","journal-title":"Circ Heart Fail."},{"issue":"10","key":"734_CR35","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","volume":"392","author":"B Greenberg","year":"2025","unstructured":"Greenberg B, Taylor M, Adler E, et al. Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N Engl J Med. 2025;392(10):972\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2412392.","journal-title":"N Engl J Med"},{"key":"734_CR36","unstructured":"Mehta A, Hughes DA, Fabry D. 2002 Aug 5 [Updated 2024 Apr 11]. In: Adam MP, Feldman J, Mirzaa GM, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132025."},{"key":"734_CR37","doi-asserted-by":"publisher","unstructured":"Pieroni M, et al. The heart in Fabry disease: mechanisms beyond storage and forthcoming therapies. Reviews Cardiovasc Med. 2022;23(6):169.\u00a0https:\/\/doi.org\/10.31083\/j.rcm2306196.","DOI":"10.31083\/j.rcm2306196"},{"issue":"11","key":"734_CR38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","volume":"24","author":"David Stevens","year":"2022","unstructured":"Stevens David, et al. Pompe disease: a clinical, diagnostic, and therapeutic overview. Curr Treat Options Neurol. 2022;24(11):573\u201388. https:\/\/doi.org\/10.1007\/s11940-022-00736-1.","journal-title":"Curr Treat Options Neurol"},{"issue":"7","key":"734_CR39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"Erik Landfeldt","year":"2020","unstructured":"Landfeldt Erik, et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(7):643\u201353. https:\/\/doi.org\/10.1007\/s10654-020-00613-8.","journal-title":"Eur J Epidemiol"},{"issue":"s2","key":"734_CR40","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"Nertiyan Elangkovan","year":"2021","unstructured":"Elangkovan Nertiyan, Dickson George. Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8(s2):S303\u201316. https:\/\/doi.org\/10.3233\/JND-210678.","journal-title":"J Neuromuscul Dis"},{"key":"734_CR41","unstructured":"FDA expands approval of gene therapy for patients with Duchenne muscular dystrophy. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy (Accessed on 24 July 2024)."},{"issue":"5","key":"734_CR42","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene Moxeparvovec gene therapy in ambulatory patients (Aged\u2009\u2265\u20094 to <\u20098 Years) with Duchenne muscular dystrophy: 1-Year interim results from study SRP-9001-103 (ENDEAVOR). Ann Neurol. 2023;94(5):955\u201368. https:\/\/doi.org\/10.1002\/ana.26755.","journal-title":"Ann Neurol"},{"key":"734_CR43","unstructured":"Second patient death reported. with gene therapy for muscular dystrophy | AP News https:\/\/apnews.com\/article\/sarepta-muscular-dystophy-duchennes-gene-therapy-255d04aa3db9bd171c9bf006328ba5d3"},{"issue":"6","key":"734_CR44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454.","journal-title":"N Engl J Med"},{"issue":"23","key":"734_CR45","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1161\/CIR.0000000000001296","volume":"150","author":"Y Kim","year":"2024","unstructured":"Kim Y, Landstrom AP, Shah SH, Wu JC, Seidman CE, American Heart Association. Gene therapy in cardiovascular disease: recent advances and future directions in science: A science advisory from the American Heart Association. Circulation. 2024;150(23):e471-80. https:\/\/doi.org\/10.1161\/CIR.0000000000001296.","journal-title":"Circulation"},{"issue":"12","key":"734_CR46","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.rec.2023.06.009","volume":"76","author":"A Argir\u00f2","year":"2023","unstructured":"Argir\u00f2 A, Ding J, Adler E. Gene therapy for heart failure and cardiomyopathies. Rev Esp Cardiol (Engl Ed). 2023;76(12):1042\u201354. https:\/\/doi.org\/10.1016\/j.rec.2023.06.009.","journal-title":"Rev Esp Cardiol (Engl Ed)"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00734-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-025-00734-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00734-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:25:20Z","timestamp":1768544720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-025-00734-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1007\/s11897-025-00734-9","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors were involved in the trials of gene therapy for Danon disease.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}